B&B Pharmacy Recalls PAPA/PGE1/PHENTO Injection Due to Sterility Concerns
Pacific Healthcare, Inc dba B&B Pharmacy is recalling PAPA/PGE1/PHENTO Injection vials because an FDA inspection found GMP violations that may affect sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a lack of assurance of sterility in an injectable medication, which poses a significant risk of serious injury or infection.
Plain-English summary
Pacific Healthcare, Inc dba B&B Pharmacy is recalling PAPA/PGE1/PHENTO (30mg/10mg/1mg/ml) Injection, 5 mL and 10 mL vials. The recall was initiated because an FDA inspection identified Good Manufacturing Practice (GMP) violations that potentially impact the product's quality and sterility.
The affected products are prescription (Rx) vials distributed in California and New Jersey. Specific lot information includes 5 mL vials with a manufacture date of 07/06/2015 and expiration date of 01/02/2016, and 10 mL vials with manufacture dates of 06/04/2015, 06/05/2015, and 07/13/2015, with corresponding expiration dates of 12/01/2015, 12/02/2015, and 01/09/2016.
Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- PAPA/PGE1/PHENTO (30mg/10mg/1mg/ml) Injection, 5 mL and 10 mL vials, Rx, B & B Health Mart Pharmacy, Bellflower, CA
- Manufacturer
- Pacific Healthcare, Inc dba B&B Pharmacy
- Category
- Drug — Injectable Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- 5 ml --- 07062015@2
- exp 1/2/2016 10 ml --- 06042015@4
- exp 12/1/2015
- 06052015@15
- exp 12/2/2015
- 07132015@3
- exp 1/9/2016
Distribution
Part of a larger recall action
This product is one of 16 recalled by Pacific Healthcare, Inc dba B&B Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 16 products in this recall →Related recalls
Same manufacturer · Pacific Healthcare, Inc dba B&B Pharmacy
See all →- SevereNandrolone Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-18
- SevereB&B Pharmacy Recalls PAPA/PHENTO Injection Due to Sterility Concerns
FDA (Drugs) · 2015-11-18
- SevereTestosterone Cypionate Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-18
- SevereStanozolol Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-18
- SeverePGE 25mcg/ml Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-18
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFallon Wellness Pharmacy Recalls PAPA/PHEN/PROST Injection Due to Sterility Concerns
FDA (Drugs) · 2016-12-14
- SevereFallon Wellness Pharmacy Recalls Papaverine Injection Due to Sterility Concerns
FDA (Drugs) · 2016-12-14
- SevereRiverpoint Pharmacy Recalls PAP/PHEN/PGE1 Injection Due to Sterility Concerns
FDA (Drugs) · 2019-07-17
- HighFDA Recalls Papaverine/Phentolamine Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2023-02-01
- SevereFDA Recalls Riverpoint Pharmacy Injection Due to Sterility Concerns
FDA (Drugs) · 2019-07-17
- SevereKey Pharmacy Recalls Papaverine/Phentolamine Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24